They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Similar documents
Choosing and delivering ering interventions entions for

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Clinical guideline Published: 27 June 2012 nice.org.uk/guidance/cg143

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update)

Clinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg120

Risk assessment for type 2 diabetes

Smoking cessation interventions and services

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72

Psychosis & Schizophrenia: The Updated NICE Quality Standard. Dr Tony Gill Mental Health Practitioner University of Leeds 7 th June 2015

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Psychosis with coexisting substance misuse

Psychosis with coexisting substance misuse. Assessment and management in adults and young people

Clinical guideline Published: 17 March 2008 nice.org.uk/guidance/cg64

Why are NICE guidelines and standards important and relevant to us?

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90

Standard Operating Procedure: Early Intervention in Psychosis Access Times

Case scenarios: Patient Group Directions

NICE guideline Published: 21 September 2016 nice.org.uk/guidance/ng56

NAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know

Clinical guideline Published: 25 May 2011 nice.org.uk/guidance/cg123

Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547

Revised Standards. S 1a: The service routinely collects data on age, gender and ethnicity for each person referred for psychological therapy.

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472

Alcohol interventions in secondary and further education

Assessment and management of selfharm

Technology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572

paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152

Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418

NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49

Extracorporeal shockwave therapy for refractory Achilles tendinopathy

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

NICE offer to STPs: CVD prevention

Early Intervention Teams services for early psychosis

NICE Guideline for Eating Disorders: Implications for Clinical Practice

Diagnosis and management of ADHD in children, young people and adults

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91

Specialist care for chronic fatigue syndrome myalgic encephalomyelitis

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

Unstable angina and NSTEMI

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Technology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516

Guideline scope Hypertension in adults (update)

SHARED CARE GUIDELINE

Surveillance report Published: 26 October 2017 nice.org.uk

Interventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

Guideline scope Smoking cessation interventions and services

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta456

The links between physical health in mental health

Technology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531

Prescribing of high-dose and combined antipsychotics for patients on forensic wards.

Clinical guideline Published: 28 January 2009 nice.org.uk/guidance/cg77

Transcription:

Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: http://pathways.nice.org.uk/pathways/psychosis-and-schizophrenia NICE Pathway last updated: 10 May 2018 This document contains a single flowchart and uses numbering to link the boxes to the associated recommendations. Page 1 of 10

Page 2 of 10

1 Adult with psychosis or schizophrenia No additional information 2 Continuing treatment and care Continue treatment and care in early intervention in psychosis services or refer the person to a specialist integrated community-based team. This team should: offer the full range of psychological, pharmacological, social and occupational interventions recommended in this guidance be competent to provide all interventions offered place emphasis on engagement rather than risk management provide treatment and care in the least restrictive and stigmatising environment possible and in an atmosphere of hope and optimism in line with NICE's recommendations on service user experience. Consider intensive case management for people with psychosis or schizophrenia who are likely to disengage from treatment or services. Review antipsychotic medication annually, including observed benefits and any side effects. Transfer When a person with psychosis or schizophrenia is planning to move to the catchment area of a different NHS trust, a meeting should be arranged between the services involved and the service user to agree a transition plan before transfer. The person's current care plan should be sent to the new secondary care and primary care providers. Support for carers See general principles of care for information on support for carers. 3 Primary care Offer people with psychosis or schizophrenia whose symptoms have responded effectively to treatment and remain stable the option to return to primary care for further management. If a Page 3 of 10

service user wishes to do this, record this in their notes and coordinate transfer of responsibilities through the care programme approach. 4 Monitoring physical health Develop and use practice case registers to monitor the physical and mental health of people with psychosis or schizophrenia in primary care. GPs and other primary healthcare professionals should monitor the physical health of people with psychosis or schizophrenia when responsibility for monitoring is transferred from secondary care, and then at least annually. The health check should be comprehensive, focusing on physical health problems that are common in people with psychosis and schizophrenia. Include all the checks recommended in baseline investigations and refer to what NICE says on monitoring for cardiovascular disease (see diet and physical activity), diabetes, obesity and respiratory disease (see chronic obstructive pulmonary disease). A copy of the results should be sent to the care coordinator and psychiatrist, and put in the secondary care notes. Identify people with psychosis or schizophrenia who have high blood pressure, have abnormal lipid levels, are obese or at risk of obesity, have diabetes or are at risk of diabetes (as indicated by abnormal blood glucose levels), or are physically inactive, at the earliest opportunity. Follow the relevant NICE recommendations on cardiovascular disease prevention, diet, hypertension, obesity, physical activity and preventing type 2 diabetes. Treat people with psychosis or schizophrenia who have diabetes and/or cardiovascular disease in primary care according to the appropriate NICE recommendations. Healthcare professionals in secondary care should ensure, as part of the care programme approach, that people with psychosis or schizophrenia receive physical healthcare from primary care as described in these recommendations. Quality standards The following quality statements are relevant to this part of the interactive flowchart. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups 6. Physical health checks for people with serious mental illness Page 4 of 10

in adults 6. Assessing physical health 5 Suspected relapse When a person with an established diagnosis of psychosis or schizophrenia presents with a suspected relapse (for example, with increased psychotic symptoms or a significant increase in the use of alcohol or other substances), primary healthcare professionals should refer to the crisis section of the care plan. Consider referral to the key clinician or care coordinator identified in the crisis plan. 6 Referral to secondary care For a person with psychosis or schizophrenia being cared for in primary care, consider referral to secondary care again if there is: poor response to treatment non-adherence to medication intolerable side effects from medication comorbid substance misuse risk to self or others. When re-referring people with psychosis or schizophrenia to mental health services, take account of service user and carer requests, especially for: review of the side effects of existing treatments psychological treatments or other interventions. 7 Secondary care Consider extending the availability of early intervention in psychosis services beyond 3 years if the person has not made a stable recovery from psychosis or schizophrenia. Page 5 of 10

8 Interventions for promoting recovery Psychological interventions Offer CBT to assist in promoting recovery in people with persisting positive and negative symptoms and for people in remission. Deliver CBT as described in how to deliver psychological interventions. Offer family intervention to families of people with psychosis or schizophrenia who live with or are in close contact with the service user. Deliver family intervention as described in how to deliver psychological interventions. Family intervention may be particularly useful for families of people with psychosis or schizophrenia who have: recently relapsed or are at risk of relapse persisting symptoms. Consider offering arts therapies to assist in promoting recovery, particularly in people with negative symptoms. Pharmacological interventions The choice of drug should be influenced by the same criteria recommended for starting treatment (see choosing antipsychotic medication). Do not routinely use targeted, intermittent dosage maintenance strategies (defined as the use of antipsychotic medication only during periods of incipient relapse or symptom exacerbation rather than continuously). However, consider them for people with psychosis or schizophrenia who are unwilling to accept a continuous maintenance regimen or if there is another contraindication to maintenance therapy, such as side-effect sensitivity. Consider offering depot/long-acting injectable antipsychotic medication to people with psychosis or schizophrenia: who would prefer such treatment after an acute episode where avoiding covert non-adherence (either intentional or unintentional) to antipsychotic medication is a clinical priority within the treatment plan. Page 6 of 10

Using depot/long-acting injectable antipsychotic medication When initiating depot/long-acting injectable antipsychotic medication: take into account the service user's preferences and attitudes towards the mode of administration (regular intramuscular injections) and organisational procedures (for example, home visits and location of clinics) take into account the same criteria recommended for the use of oral antipsychotic medication (see choosing antipsychotic medication), particularly in relation to the risks and benefits of the drug regimen initially use a small test dose as set out in the BNF or SPC. 9 Employment, education and occupational activities Offer supported employment programmes to people with psychosis or schizophrenia who wish to find or return to work. Consider other occupational or educational activities, including prevocational training, for people who are unable to work or unsuccessful in finding employment. Mental health services should work in partnership with local stakeholders, including those representing black, Asian and minority ethnic groups, to enable people with mental health problems, including psychosis or schizophrenia, to stay in work or education and to access new employment (including self-employment), volunteering and educational opportunities. Routinely record the daytime activities of people with psychosis or schizophrenia in their care plans, including occupational outcomes. Quality standards The following quality statement is relevant to this part of the interactive flowchart. in adults 5. Supported employment programmes 10 Back to overview See / overview Page 7 of 10

Glossary CBT cognitive behavioural therapy ECG electrocardiogram CAMHS child and adolescent mental health services HbA1c glycosylated haemoglobin BNF British National Formulary BNFC British National Formulary for Children SPC summary of product characteristics Sources in adults: prevention and management (2014) NICE guideline CG178 Page 8 of 10

Your responsibility Guidelines The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Technology appraisals The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take these recommendations fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this interactive flowchart is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Commissioners and/or providers have a responsibility to provide the funding required to enable the recommendations to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to Page 9 of 10

have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Medical technologies guidance, diagnostics guidance and interventional procedures guidance The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take these recommendations fully into account. However, the interactive flowchart does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Commissioners and/or providers have a responsibility to implement the recommendations, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this interactive flowchart should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Page 10 of 10